KLOW combines the BPC-157 and TB-500 repair pair with KPV, a peptide studied for its anti-inflammatory activity.
This page covers what each peptide contributes, where the evidence stands, our view on using it, and how it compares to Wolverine. It covers why — as with any injected peptide — the source matters as much as the molecule.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
KLOW is an injectable peptide blend that combines three peptides: BPC-157, TB-500, and KPV. The first two are the repair pair used in Wolverine — BPC-157, a peptide based on a protein found in gastric juice and studied since the 1990s for tissue repair.
TB-500 is the active fragment of Thymosin Beta-4, a peptide the body produces naturally, studied for the migration of repair cells to injured tissue.
KPV is the third component: a short peptide derived from alpha-melanocyte-stimulating hormone (α-MSH), studied for anti-inflammatory activity. It is what distinguishes KLOW from Wolverine.
KLOW is used to support the body's recovery and repair processes, with an added anti-inflammatory and gut-oriented component contributed by KPV. The reason to add KPV to the repair pair is to target inflammation and gut health alongside recovery — so it is chosen for patients whose goal includes both, rather than recovery alone.
These are the reported and studied applications of the component peptides; they are not established, FDA-approved indications.
Benefit cluster: recovery & repair · inflammation · tendon, ligament & joint support · gut health
KLOW acts across complementary pathways. In animal and laboratory studies, BPC-157 has been associated with new blood-vessel formation, tissue regeneration, and reduced inflammation. TB-500 has been associated with the migration of repair cells to injured tissue and with reduced inflammation and scarring.
KPV has been associated with anti-inflammatory activity, including effects on inflammatory signaling and the gut barrier. This picture is drawn from preclinical research and has not been established for this blend in human clinical trials.
BPC-157 is a synthetic peptide based on a protein found in gastric juice. In animal and laboratory studies it has been associated with tissue repair — new blood-vessel formation, recovery in muscle, tendon, ligament, and bone — reduced inflammation, and support of the gut lining. It is the more structural-repair component of the blend.
TB-500 is the active fragment of Thymosin Beta-4, a peptide the body produces naturally. In preclinical research it has been associated with cell migration to injured tissue, support of the cells involved in healing, and reduced inflammation and scarring. It is oriented toward mobility and whole-body recovery.
KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). In preclinical research it has been studied for anti-inflammatory activity, including effects on inflammatory signaling and the intestinal barrier. It is the least-studied of the three, and its evidence base is earlier; it is included to add an anti-inflammatory and gut-oriented component to the repair pair.
KLOW's three peptides sit at different points on the evidence scale.
The repair pair has the stronger record; KPV's evidence is earlier and lighter. Across all three, human trial evidence is limited. Our own practice experience with KLOW specifically is limited compared with Wolverine, which uses the same repair pair without KPV.
Our verdict: KLOW is a reasonable option when an anti-inflammatory or gut-oriented component is part of the goal, on top of recovery. The BPC-157/TB-500 pair is the part we have the most experience with and find effective for healing and recovery in many, if not most, patients.
KPV is added for its anti-inflammatory activity, though its evidence is earlier and our own experience with the KPV addition is more limited.
The overall evidence is preclinical and anecdotal rather than from human trials, so we treat KLOW as promising rather than proven. We use it as one targeted tool, chosen for a defined goal within a considered plan.
Where the objective is primarily musculoskeletal repair, Wolverine, the same repair pair without KPV, is often sufficient and is our more established protocol.
— Dr. David Oliak, board-certified physician and surgeon
With any injected peptide, the source is a safety issue, not a detail. We prescribe KLOW compounded for human use by a licensed pharmacy, on a prescription, and supervise its use.
Most peptides sold online are labeled "research use only" — not for human use — and are produced without a regulatory framework to confirm their contents, purity, or sterility.
Reported side effects of KLOW are generally mild and most commonly involve local irritation at the injection site. Because human data is limited, the long-term safety profile is not fully established. KLOW is not an FDA-approved medication.
Peptide therapy is not appropriate for everyone; your provider will review your history, medications, and goals before prescribing. Why "research use only" peptides are a problem →
Let's begin
Whether KLOW fits your goals, at what dose and cycle, is decided in a consultation. It is set within a plan built around what you are trying to achieve — KLOW for a combined recovery-and-inflammation goal, or as one part of a broader plan when your goals call for it.
Book a peptide consult for a targeted goal, or start with a comprehensive evaluation when you want the fuller picture first. To speak with us first, call 714-671-2005.
Wolverine (BPC-157 / TB-500) — the same repair pair without KPV
GHK-Cu and GLOW — for skin, hair, and repair
Why "research use only" peptides are a problem
What a comprehensive evaluation includes